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Kynurenine Increases Matrix Metalloproteinase-1
and -3 Expression in Cultured Dermal Fibroblasts
and Improves Scarring In Vivo
Yunyuan Li1, Ruhangiz T. Kilani1, Elham Rahmani-Neishaboor1, Reza B. Jalili1 and Aziz Ghahary1
We previously demonstrated that the formation of hypertrophic scarring on the wounds of a rabbit ear fibrotic
model was significantly reduced by grafting a bilayer skin substitute expressing indoleamine 2,3-dioxygenase
(IDO). Here, we hypothesize that the improved healing quality is due to extracellular matrix modulatory effect of
IDO-mediated tryptophan metabolites. To test this hypothesis, a series of in vitro and in vivo experiments
were conducted and the findings revealed a significant increase in the expression of matrix metalloproteinase 1
(MMP-1) in fibroblasts either transduced with human IDO gene or cultured with conditioned media obtained
from IDO-expressing cells. Consistent with this finding, kynurenine (Kyn) treatment markedly increased the
levels of MMP-1 and MMP-3 expression through activation of the MEK (mitogen-activated protein kinase (MAPK)/
extracellular signal–regulated kinase (ERK) kinase)-ERK1/2 MAPK signaling pathway. On the other hand, Kyn
significantly suppressed the expression of type I collagen in fibroblasts as compared with that of control. To test
the anti-fibrogenic effect of Kyn in an in vivo model, rabbit ear fibrotic wounds were topically treated with cream
containing 50mg Kyn per l00ml of cream per wound. The result showed a marked improvement in scar formation
relative to the controls. These findings collectively suggest that Kyn can potentially be used as an anti-fibrogenic
agent for treating hypertrophic scarring.
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INTRODUCTION
Matrix metalloproteinases (MMPs) are a family of zinc-depen-
dent and neutral endopeptidases. So far, 420 members of the
MMP family have been reported. MMPs have an important role
in tissue remodeling through the degradation of extracellular
matrix (ECM) components. They are able to cleave all types of
ECM molecules and other substrates, such as growth factors,
cytokines, and additional proteases (Sternlicht and Werb,
2001). In normal tissues, the expression and activity of MMPs
are nearly absent. However, under certain physiological con-
ditions such as fetal tissue development, tissue regeneration,
and wound repair, their expression and activity are significantly
higher. Under pathologic conditions, increased MMP activity
has been noted in numerous disease processes, including tumor
invasion and metastasis, rheumatoid arthritis, periodontitis,
autoimmune blistering disorder of the skin, osteoarthritis, and
chronic ulcerations (Johansson et al., 2000).
Although, the role of MMPs in prevention and treatment of
fibrotic disorders is still controversial, some studies have
shown that the stimulation of MMP-1 expression through a
therapeutic factor, or the direct application of purified MMP-1,
both have a beneficial impact in treating hypertrophic scarring
(Iimuro et al., 2003). For example, relaxin, a small peptide,
which upregulates MMP-1 expression in fibroblasts (Unemori
and Amento, 1990), has been demonstrated to have potential
anti-fibrotic properties in vivo (Samuel, 2005). Similarly, onion
extract, which is known to reduce scar formation, has been
recently associated with the activity of stimulating MMP-1
expression in vitro and in vivo (Cho et al., 2010). In addition,
the application of a purified recombinant proMMP-1 has also
shown a positive effect on the treatment of established liver
fibrosis in rats (Iimuro et al., 2003). These data suggest that
MMP1-stimulating factors may have an anti-fibrotic effect.
To prevent or treat dermal fibrotic disorders, we have
previously conducted a series of experiments to identify any
factors that may either increase the expression of proteases in
dermal fibroblasts, reduce matrix synthesis, or both (Ghahary
et al., 2004; Ghaffari et al., 2009; Rahmani-Neishaboor et al.,
2010). Our findings revealed that animal wounds that have
been engrafted with indoleamine 2,3-dioxygenase (IDO)-
expressing skin substitutes had a higher level of MMP-1
expression, less inflammation, and improved scarring as
compared with the controls (Li et al., 2006; Forouzandeh
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et al., 2010; Chavez-Mun˜oz et al., 2012). IDO is a rate-
limiting enzyme converting the essential amino acid L-
tryptophan into kynurenine (Kyn). Normally, IDO is absent
in almost all tissues, but it is highly expressed in trophoblast
cells and the endothelium cells of placenta (Munn et al.,
1998, Honig et al., 2004). As Kyn is releasable from the
IDO-expressing skin substitute, here we hypothesize that
scar improvement seen in IDO-expressing skin substitute
engrafted on rabbit ear fibrotic model is due to ECM
modulating effects of Kyn for dermal fibroblasts. To address
this hypothesis, in this study, a series of in vitro and in vivo
experiments have been conducted and showed that Kyn
significantly increases the expression of MMP-1 and MMP-3;
while reduces the expression of collagen in dermal fibroblasts.
The findings of further experiments showed that the MMP-
stimulating effect of Kyn is due to activation of MEK (mitogen-
activated protein kinase (MAPK)/extracellular signal–regulated
kinase (ERK) kinase)-ERK1/2 MAPK signaling pathway. Finally,
the result of the topical application of Kyn on rabbit ear
fibrotic wounds markedly improved scarring.
RESULTS
IDO upregulates MMP-1 expression in human dermal fibroblasts
To assess the effect of IDO on MMP-1 expression, a human
IDO recombinant adenoviral vector was used for gene
transduction in human dermal fibroblasts by a procedure
previously reported (Li et al., 2004). Transfection efficiency
was evaluated by detecting IDO protein expression and
its activity through western blot analysis and the Kyn
measurement in conditioned media, respectively. As shown
in Figure 1a left panel, the IDO protein was expressed in IDO
adenovirus-transduced fibroblasts, but undetectable in control
and mock adenovirus-transduced fibroblasts. The level of Kyn,
an index for IDO activity, was significantly higher in IDO
adenovirus-transduced fibroblasts (14.3±0.46mg ml–1, n¼3)
compared with those in untransduced or mock-transduced
controls (Figure 1a, right panel).
We then examined the expression of MMP-1 in control,
mock-transduced and IDO-expressing fibroblasts by using
western blot analysis. As shown in Figure 1b, there was a
more than ninefold increase in MMP-1 expression in IDO-
expressing fibroblasts (12.56±2.37, n¼ 3) as compared with
those in mock-transduced (1.37±0.59, n¼3) and untreated
control fibroblasts (1±0, n¼3). This finding suggests that
upregulation of MMP-1 expression in IDO-expressing fibro-
blasts is not due to adenovirus infection, as the mock-
transduced fibroblasts showed no significant difference in
MMP-1 expression from the untreated fibroblasts.
IDO is an intracellular enzyme that converts tryptophan into
Kyn. Therefore, it must be clarified whether the effect of
MMP-1 stimulation in IDO-expressing fibroblasts is due to the
IDO protein itself or to tryptophan metabolites. To address
this, conditioned media from both IDO-expressing fibroblasts
and controls were collected after 48 hours. A combination of
90% collected conditioned media and 10% fresh media was
then used to treat dermal fibroblasts. Cells were harvested
48 hours after treatment. As shown in Figure 1c, a significant
increase in MMP-1 expression was observed in cells treated
with conditioned media from IDO-transduced fibroblasts
(2.06±0.62, n¼3) as compared with those in either mock-
transduced (1.16±0.31, n¼3) or untreated control fibroblasts
(1±0, n¼ 3). This result suggests that a factor or factors in
conditioned media from IDO adenovirus-infected fibroblast
rather than intracellular IDO protein is responsible for an
increased level of MMP-1 expression in fibroblasts.
Kyn but not depletion of tryptophan induces MMP-1 expression
in human dermal fibroblasts
IDO is an enzyme converting tryptophan into Kyn. To
examine what factor (either depletion of tryptophan or
increase of Kyn) is responsible for IDO upregulation of
MMP-1 expression, fibroblasts were grown in either trypto-
phan-depleted cultured media or regular media with various
concentrations of Kyn. Cells were then evaluated for MMP-1
expression by western blotting. As shown in Figure 2c, there
was no significant difference in the expression of MMP-1
between fibroblasts grown in the presence of 25mg ml–1
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Figure 1. IDO upregulation of matrix metalloproteinase 1 (MMP-1)
expression in human dermal fibroblasts. (a) Fibroblasts were transduced with
either nothing (C), adenoviral vector (V), or a vector bearing the human
indoleamine 2,3-dioxygenase (IDO) recombinant gene (IDO) for 48 hours.
IDO and its activity were detected by western blotting (left panel) and
measurement of the kynurenine (Kyn) levels (right panel), respectively.
(b) Either untreated, adenoviral vector, or IDO-transduced fibroblasts were
lysed after being cultured for 48 hours, and the expression of MMP-1 was
detected by western blotting. (c) Fibroblasts were incubated with the
conditioned media taken from either control, empty vector, or IDO adenoviral
vector-transduced fibroblasts for 48 hours. The expression of MMP-1 was
analyzed by western blotting. b-Actin was used as a loading control in
a–c. *Po0.001.
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tryptophan or in the tryptophan-depleted cultured media.
However, the MMP-1 expression was significantly increased
in response to different doses (25–150mg ml–1) of Kyn
(Figure 2a and b). These findings suggest that the presence
of Kyn, but not tryptophan depletion, contributes to the
upregulation of MMP-1 in IDO-expressing cells. Furthermore,
we found that as little as 12.5mg ml–1 of Kyn could stimulate
MMP-1 expression in dermal fibroblasts (data not shown). This
concentration of Kyn is similar to that detected in conditioned
media from IDO-expressing fibroblasts (Figure 1a, right panel).
The stimulation of MMP-1 in fibroblasts is thus clearly specific
to Kyn as the addition of various concentration of tryptophan
with a similar structure failed to increase the expression of
MMP-1 in dermal fibroblasts (Figure 2d).
Effects of Kyn on MMP-2 and MMP-3 expressions in dermal
fibroblasts
To investigate whether Kyn also affects the expression of other
MMPs, we treated dermal fibroblasts with Kyn at similar
concentrations to those used in Figure 2. Western blotting
was used to detect MMP-2 and MMP-3 expression using
untreated cells as controls. As shown in Figure 3a, there was
no significant difference in MMP-2 expression between Kyn-
treated and -untreated fibroblasts. However, under similar
conditions, Kyn treatment significantly increased MMP-3
expression in dermal fibroblasts in a dose-dependent manner
(Figure 3b). Furthermore, to test whether the increased levels
of MMPs in Kyn-treated fibroblasts were followed by
increased MMP activity, conditioned media from fibroblasts
in the presence or absence of 50mg ml–1 of Kyn were collected
48 hours after treatment. The MMP activity in the conditioned
media was detected by a SensoLyte 520 generic MMP assay
kit using a 5-FAM/QXL 520 fluorescence resonance energy
transfer peptide as a MMP substrate. As shown in
Supplementary Figure S1 online, the mean activity of MMPs
in conditioned media from the Kyn-treated fibroblast was
significantly higher than in the control media. This indicates
that the increased MMPS in fibroblasts treated by Kyn have
enzymatic activity.
Mesenchymal and epithelial cells respond differently to Kyn
treatments
To determine what types of cells are sensitive to Kyn-induced
MMP-1 expression, both mesenchymal cells (such as an
immobilized lung fibroblast cell line IMR-90 and fibroblast-
like synoviocytes) and epithelial cells (such as lung epithelial
carcinoma cell line A549, primary dermal keratinocytes,
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Figure 2. Effects of kynurenine (Kyn) and tryptophan on matrix
metalloproteinase 1 (MMP-1) expression in human dermal fibroblasts.
(a, b) Dermal fibroblasts were cultured in the presence of various
concentrations of Kyn for 48 hours. Cells were harvested and lysed. Western
blotting was performed. The ratio of MMP-1 to b-actin is presented in b.
(c) Dermal fibroblasts were cultured in the presence or absence of tryptophan
(25mg ml–1) for 48hours. Cells were harvested and lysed. MMP-1 expression
was evaluated by western blotting. (d) Fibroblasts were cultured in the presence
of different concentrations of tryptophan for 48hours. The expression of MMP-1
was evaluated by western blotting. b-Actin was used for a loading control in
all panels.
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Figure 3. Effects of kynurenine (Kyn) on matrix metalloproteinase 2 (MMP-2)
and MMP-3 expression in human dermal fibroblasts. Dermal fibroblasts were
cultured in the presence of various concentrations of Kyn for 48 hours. Cells
were harvested and lysed. Western blotting was performed by using either a
monoclonal rabbit anti-human MMP-2 antibody (a) or a monoclonal mouse
anti-MMP-3 antibody (b). (c) Shows the ratio of MMP-3 expression to b-actin
for three independent experiments. b-Actin was used for a loading control in
all experiments.
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human immobilized keratinocyte cell line HACAT, and head
and neck squamous cell carcinoma cell line UMSCC) were
used. As with the dermal fibroblasts, MMP-1 expression in
synoviocytes and IMR-90 were upregulated by Kyn treatments
at concentrations of 12.5–150mg ml–1, as shown in Supple-
mentary Figure S2 online. However, the expression of MMP-1
in all epithelial cells tested, including dermal keratinocytes,
HACAT, A549, and UMSCC, did not significantly differ from
the untreated controls in response to the various concentration
of Kyn (Supplementary Figure S3 online). These results suggest
that there is a difference between mesenchymal and epithelial
cells in response to Kyn-stimulating MMP-1 expression.
Identification of phosphorylated signal molecules by phosphor-
kinase array in cells treated with Kyn
To determine the possible mechanism of Kyn upregulated
MMP-1 expression in dermal fibroblasts, we analyzed the
activation of multiple serine, threonine, or tyrosine kinases,
using a phosphor-kinase array. This array gives the possibility
of simultaneously detecting the activation status of 46 different
protein kinases and their downstream transcript factors. As
shown in Supplementary Figure S4 online, after 1 hour of
treatment in dermal fibroblasts with Kyn, ERK1/2 was activated.
To confirm these results from the phosphor-kinase array,
dermal fibroblasts were treated with 100mg ml–1 of Kyn at
different times. Immunoblotting analysis, using a different
antibody from those placed on the array, was then used to
detect the phosphorylation of ERK1/2 and its upstream
molecule MEK. As shown in Figure 4, ERK1/2 was phosphory-
lated in cells treated with Kyn. The result was further
confirmed by detection of the ERK1/2 upstream signal mole-
cule MEK phosphorylation in cells treated with Kyn (Figure 4).
Both ERK1/2 and MEK showed similar patterns of activation,
with a peak at 8 hours following Kyn treatments (Figure 4).
Addition of inhibitors for MEK-ERK1/2 phosphorylation negates
the effects of Kyn-stimulating MMP-1 expression in dermal
fibroblasts
In another set of experiments, we tested whether the activation
of the MEK-ERK1/2 MAPK pathway by Kyn is associated with
Kyn-stimulating MMP-1 expression in dermal fibroblasts. To
do this, we examined the effects of inhibitors of either MEK or
ERK1/2 phosphorylation on Kyn-stimulating MMP-1 expres-
sion. As shown in Figure 5a, the addition of PD98059, a
specific inhibitor for ERK1/2 activation effectively prevented
the stimulatory effect of Kyn on MMP-1 expression, in a dose-
dependent manner. Similarly, treatment of cells with 10 and
30mM of U0126, a specific inhibitor for MEK activation, also
significantly reduced the upregulation of MMP-1 expression by
Kyn (Figure 5b). These results show that the activation of the
MEK-ERK1/2 signaling pathway contributes to the upregulation
of MMP-1 expression induced by Kyn in dermal fibroblasts.
Effects of Kyn on collagen expression in dermal fibroblasts and
fibroblast proliferation
Before studying its anti-fibrotic role in vivo, we tested whether
Kyn has any effect on collagen expression and cell prolifera-
tion. As shown in Supplementary Figure S5 online, the
addition of Kyn 25–150mg ml–1 remarkably decreases the
expression of type 1 procollagen. However, it had no
significant effect on fibroblast proliferation, even when the
cells were cultured at concentrations up to 150mg ml–1 of Kyn
(Supplementary Figure S6 online).
0 0.5 4 8 16 24 Time (hours)
P-MEK
P-ERK1/2
β-Actin
1 2
Figure 4. Kynurenine (Kyn) stimulation of MEK (mitogen-activated protein
kinase (MAPK)/extracellular signal–regulated kinase (ERK) kinase) and ERK1/2
phosphorylation in human dermal fibroblasts. Dermal fibroblasts were
cultured in the presence of 100mg ml–1 of Kyn at indicated time points. Cells
were harvested and lysed. Western blotting was performed by using either
phosphorylated-MEK or phosphorylated-ERK1/2 antibody. b-Actin was used as
a loading control.
Kynurenine
(100 μg ml–1)
PD98059 (μM)
PD98059 (30 μM) +
+
+
+
+–––– +
+
+
+
+
U0126 (30 μM)
U0126 (10 μM)
MMP-1
β-Actin
MMP-1
β-Actin
– – – – + + + +
0 1 10 30 0 1 10 30
Figure 5. Addition of MEK (mitogen-activated protein kinase (MAPK)/
extracellular signal–regulated kinase (ERK) kinase) or ERK1/2 phosphorylation
inhibitors negates the effect of kynurenine (Kyn)-stimulating MMP-1
expression in dermal fibroblasts. (a) Dermal fibroblasts were cultured in the
absence or presence of 100mg ml–1 Kyn with or without various concentrations
of PD98059. (b) Dermal fibroblasts were cultured in the absence or presence of
100mg ml–1 Kyn with or without 30mM of PD98059 (ERK1/2 inhibitor), 30mM of
U0126 (MEK inhibitor), or 10mM of U0126. MMP-1 expression was detected
by western blot. b-Actin was used as a loading control for all experiments.
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Figure 6. Clinical appearance and histology of wound and scars. Rabbit ear wounds were treated daily with either nothing, carboxymethyl cellulose (CMC) gel
alone, or 50mg of kynurenine (Kyn) in 0.1 ml of CMC gel started from day 8 for a total of 3 weeks. (a) The clinical appearance of wounds receiving either nothing
(cytotoxic T lymphocyte (CTL)), CMC gel (Gel), or Kyn in CMC gel (Kyn) on day 28. (b) The microscopic histology of wounds as described in c. Bar¼ 100mm.
(c) Scar elevation index (SEI) was measured. Mean±SD of SEI for untreated, CMC gel, and Kyn in CMC gel-treated wounds are depicted. *Shows a significant
difference between Kyn-treated and -untreated controls (Po0.001); **shows a significant difference between Kyn and CMC gel control groups (Po0.01).
(d) Masson’s trichrome stained full-thickness skin sections from either untreated skin wound (left panels), cream-treated skin wound (middle panels), or kynurenine
(Kyn)-treated wound (right panels). Bar ¼ 100mm. (e) Total hydroxyproline content. Skin from either untreated wounds (total four wounds), cream-treated wounds
(total four wounds), or Kyn-treated wounds (total eight wounds) was used to measured hydroxyproline content as mentioned in the Supplementary Text online.
*Po0.01.
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Topical application of Kyn on skin wounds in a rabbit ear fibrotic
model reduces scarring
As treatment of dermal fibroblasts with Kyn showed an
increase in both the MMP-1 and MMP-3 expression as well
as a decrease in type-1 procollagen expression, we were
interested to know whether Kyn can be used as an anti-fibrotic
agent for the treatment or prevention of hypertrophic scarring.
To achieve this, as described previously (Kloeters et al., 2007;
Xie et al., 2008; Rahmani-Neishaboor et al., 2010), a rabbit
ear hypertrophic scar model was used. Wounds were treated
daily with 0.1 ml of carboxymethyl cellulose gel containing
50mg of Kyn for 3 weeks starting at day 8 after wounding. The
dose of 50mg Kyn per wound was matched with that used in
an in vitro system with an optimum outcome. The result
showed no significant difference to wound closure in Kyn-
treated wounds as compared with that of either untreated or
carboxymethyl cellulose gel-treated controls (data not shown).
However, as shown in Figure 6a and b, significantly less
scarring was seen in wounds treated with Kyn than either non-
treated wounds or the vehicle-only control wounds after 3
weeks. The average scar elevation index (SEI) was significantly
reduced in the Kyn-treated group (1.172±0.156, n¼8) as
compared with the vehicle-only control group (1.978±0.442,
n¼4, Po0.01) and the untreated group (2.098±0.324, n¼4,
Po0.001; Figure 6c). Masson’s trichrome staining for collagen
revealed a significant reduction in collagen content in wounds
treated with Kyn, compared with those wounds receiving
either no treatment or gel alone (Figure 6d). Consistent with
this finding, the hydroxyproline content (used as an index
for tissue collagen content) was significant lower in wounds
treated with Kyn compared with those wounds receiving
either no treatment or gel alone (Figure 6e).
Finally, we demonstrated that topical application of Kyn in
a rabbit ear fibrotic model decreased the expression of type-1
a1 collagen and increased the expression of MMP-1, as
compared with those in wounds received either no treatment
or gel alone (Supplementary Figure S7 online). These results
further support the supposition that Kyn could potentially be
used as an anti-fibrotic factor for treating hypertrophic scarring
and even keloid, as frequently seen in patients with burn
injuries or surgical incisions.
DISCUSSION
There is now compelling evidence that IDO has a critical role
in regulating immune tolerance to foreign antigens within the
tissue microenvironment (Johnson et al., 2009). Some studies
also found a link between IDO enzyme activity and tumor
immunotolerance (Prendergast, 2008). In this study, we
demonstrated that Kyn, a metabolite of tryptophan, induces
the expression of MMP-1 and MMP-3 through acti-
vation of the MEK-ERK1/2 signaling pathway in fibroblasts.
To our knowledge, a relationship between Kyn and MMP-1
and MMP-3 in any cells was previously unreported.
In this study, we found that Kyn-induced MMP-1 and
MMP-3 but not MMP-2 expression in dermal fibroblasts
(Figures 2 and 3). This is particularly interesting since a
number of studies have demonstrated that MMP-2 has a
different impact on fibrosis than does MMP-1. Note that
fibrosis is characterized by ECM accumulation, consisting of
depositing of fibrillar matrix predominantly of the interstitial
collagens type 1 and 3, and that collagens are relatively
resistant to most proteases but sensitive to interstitial collage-
nases such as MMP-1 in human and MMP-13 in rats. In
fibrosis, MMP-1 and MMP-2 usually show a different pattern
of expression. For example, in hepatic fibrosis, the expression
of MMP-1 is minimal, however, MMP-2 is constitutively
expressed by activated stellate cells (Milani et al., 1994;
Preaux et al., 1999). Similarly, augmented expression of
MMP-2 was found in skin fibrosis (Kelly et al., 2010) and
lung fibrosis (Oggionni et al., 2006). In addition, MMP-2 and
MMP-9 have been used as serum markers for skin fibrosis in
patients with severe burn trauma (Ulrich et al., 2003), and
MMP-2-deficient fibroblasts exhibit an anti-fibrotic response
to the connective tissue growth factor (Droppelmann et al.,
2009). MMP-2 has therefore been considered as an enzyme,
in that it degrades normal tissue structure and facilitates the
progression of fibrosis. In contrast with MMP-2, however,
the expression and activity of MMP-1 in fibrosis are very
limited. Modulation and local stimulation of MMP-1, to
degrade the accumulated fibrillar collagens, have been
shown to have a promising impact on the treatments
of fibrotic diseases. Iimuro et al. (2003) reported a
successful treatment of established liver fibrosis in rats by
using purified recombinant adenovirus-expressing proMMP-1
directly. Similar results were obtained in muscle fibrosis of
mice by local delivery of either proMMP-1 or active MMP-1
(Kaar et al., 2008). Recently, we also showed that topical
application of stratifin, a MMP-1 and MMP-3-stimulating
factor, significantly reduced scar formation in a rabbit ear
healing model (Rahmani-Neishaboor et al., 2010). These
studies strongly support our findings that Kyn with MMP-1
and MMP-3 stimulatory effect may have an anti-fibrotic value
for treatment of dermal fibrosis.
In fact, in this study, we have also shown that topical
application of Kyn in a previously described rabbit ear fibrotic
model remarkably reduces scar formation (Figure 6). A higher
MMP-1 expression and lower collagen content than the
controls have been demonstrated in wounds receiving Kyn.
Induction of MMP-1 expression and reduction of collagen
production are the key factors contributing to the anti-fibrotic
role of Kyn. Results of our in vivo experiments were further
supported by our previous report showing that wounds in
animal models healed faster and had less inflammation and
scar formation when wounds received IDO-expressing skin
substitutes (Li et al., 2006; Forouzandeh et al., 2010; Chavez-
Mun˜oz et al., 2012). However, as shown in this study, Kyn not
only upregulates MMP-1 and MMP-3 expression, but also
downregulates the synthesis of type-1 collagen. Thus, in this
study, we could not determine which mechanism contributes
to the remarkable reduction of ECM seen in Kyn-treated
wounds in a rabbit ear fibrotic model.
In summary, our results showed that tryptophan metabolite
Kyn, along with its well-known immunoregulatory function,
can upregulate MMP-1 and MMP-3 expression and reduce
type 1 procollagen production in mesenchymal cells. We also
demonstrated that the activation of MEK-ERK1/2 MAP kinase
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signal pathway by Kyn is responsible for its effect on MMP-1
expression. Furthermore, in a rabbit ear wound healing model,
topical Kyn treatment reduced scarring remarkably. These
findings collectively indicate Kyn’s potentially significant
therapeutic value for fibrotic disorders.
MATERIALS AND METHODS
Detailed materials and methods were described in the Supplementary
data online.
Cell cultures
Cultures of human foreskin fibroblasts were established as described
previously (Li et al., 2006).
Gene transfection by adenoviral vector
The construction of IDO-expressing adenoviral vectors, transduction
of fibroblasts, and evaluation of IDO expression and its activity have
been previously described (Li et al., 2004).
Western blot analysis
Western blot was performed as previously described (Li et al., 2004).
The primary antibodies used in this study were: mouse monoclonal
anti- human MMP-1 (R&D Systems, Minneapolis, MN), mouse
monoclonal anti- human MMP-3 (R&D Systems), rabbit monoclonal
anti-human MMP-2 (Epitomics, Burlingame, CA), rabbit polyclonal
anti-phospho-MEK1/2, Ser217/221 (Cell Signaling Technology,
Danvers, MA), rabbit polyclonal anti-phospho-p44/42 MAPK (Thr202/
Tyr204; Cell Signaling Technology), mouse monoclonal anti-human
procollagen type 1 a1 anti-aminopropeptide antibody (Developmental
Studies Hybridoma Bank (Iowa City, IA), and monoclonal anti-b-actin
(Sigma-Aldrich, St Louis, MO). The secondary antibodies were either
goat anti-mouse IgG (Hþ L) horseradish peroxidase conjugate or goat
anti-rabbit IgG (Hþ L) horseradish peroxidase conjugate (Bio-Rad
Laboratory, Mississauga, ON, Canada). Secondary antibodies were
used at a concentration of 1:3000.
Rabbit ear hypertrophic scar model and topical application of
Kyn
Female rabbits (New Zealand white) were used for this study. The
protocol was reviewed and approved by the University of British
Columbia Animal Care Committee. The rabbit ear model of hyper-
trophic scar was generated as described previously (Rahmani-
Neishaboor et al., 2010). Four full thickness wounds were
generated on the ventral side of each ear using an 8-mm dermal
biopsy punch. Antibiotics were applied on wounds daily until Kyn
treatment was started.
Kyn in carboxymethyl cellulose gel (Rahmani-Neishaboor et al.,
2010) with a concentration of 500mg ml–1 was daily applied topically
to the wounds of the experimental group (0.1 ml per wound) for 3
weeks starting at 1 week after wounding. The wounds of the control
group received daily treatment with an equal amount of gel alone.
The animals were killed on week 3 after treatments. The SEI was
quantified by measuring the scar area from the hematoxylin and
eosin–stained tissue section. The SEI consists of the ratio of the tissue
height of the total wound to that of the normal tissue below the
hypertrophic scar. A SEI of 1 indicates that the scar height is equal to
the surrounding unwounded dermis; an SEI41 indicates a raised
hypertrophic scar.
Statistic analysis
All data are presented as a mean±SD of at least three independent
experiments. Data were analyzed using the analysis of variance
Tukey–Kramer multi-comparisons test to compare the means between
study groups and their controls. A P-value of o0.05 was considered
as statistically significant difference between mean values.
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